Vanda Drugs Inc. (Vanda), a main worldwide biopharmaceutical organization, reported that the US Patent and Brand name Office has given a notification of recompense for its Ponvory (ponesimod) patent application, number 17/962,968, covering...
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) have approved the diabetes and weight management drug Mounjaro (tripeptide), a four-part version (with one month of treatment) of the Mounjaro KwikPen.
Abbott said he had received approval from the United States. The Food and Drug Administration (FDA) will launch the Liberta RC DBS system, the world's most minor deep brain stimulation (DBS)
The US Food and Drug Administration (FDA) have approved Dupixent (dupilumab) for the treatment of pediatric patients 1 to 11 years of age and weighing 15 kg or more with eosinophilic esophagitis (EoE).
Ascletis Pharma Inc. was the first patient enrolled in a Phase 3 clinical trial of ASC40 (Denifanstat) to treat moderate to severe acne vulgaris at Fudan Huashan University Hospital.
According to multiple people who are aware of the development, the contract drugmaker Inventia Healthcare, which is based in Mumbai, is being considered for acquisition by the US buyout fund Platinum Equity Advisors at a valuation of 2,500 crore...
Harbour BioMed, a worldwide biopharmaceutical business, announced that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to start the first-in-human (FIH) clinical study in the US for bispecific...
Zydus Lifesciences said that it has gained FDA permission to offer a generic medicine to treat postherpetic neuralgia. Zydus Lifesciences announced in a regulatory filing that the US Food and Drug Administration (USFDA) has granted final...
Although prevention is essential, treatment of obesity classes 2 to 3 defies traditional methods with a success rate of 1 in 100 and is not surgically feasible for everyone due to surgical complications.
Glenmark Pharmaceuticals Ltd said its subsidiary Glenmark Specialty SA (GSSA) has entered into a licensing agreement with Jiangsu Alphamab Biopharmaceuticals Co and 3D Medicines (Beijing) Co Ltd for KN035 (Envafolimab),
, CDSCO.jpg)
.jpg)